plamotamab (XmAb13676) - J&J
Plamotamab: Expiry of patents in US/ex-US in 2035 (Xencor) - Mar 1, 2023 - Annual Report 2022 
Patent Hematological Malignancies • Oncology
https://investors.xencor.com/static-files/000fb01e-4592-43c0-b653-0e18f12108fe
 
Mar 1, 2023
 
 
e84c4024-e199-4274-b8f3-64d32d268d1b.png